Ergomed's Co-Development Partner Aeterna Zentaris Obtains Recommendation from Data Safety Monitoring Board to Continue ZoptEC Phase 3 Trial in Advanced Endometrial Cancer
Follows second interim analysis Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer
Guildford, UK - 14 October 2015: Ergomed plc (LSE: ERGO or 'Ergomed'), a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is pleased to note that its co-development partner Aeterna Zentaris (NASDAQ: AEZS) (TSX: AEZ), has received a recommendation from the Data Safety Monitoring Board (DSMB) to continue the Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) pivotal study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer.
Dr Miroslav Reljanovic, Chief Executive Officer of Ergomed, commented: "Having completed the recruitment ahead of schedule, the trial is progressing as planned and we are very pleased with this recommendation from the DSMB to continue the Phase 3 ZoptEC study. We believe that zoptarelin doxorubicin has the potential to provide treatment for advanced, recurrent endometrial cancer, and look to continue progressing this study with Aeterna Zentaris."
Quelle: www.londonstockexchange.com/exchange/news/...ail/12538541.html